Safety, Pharmacokinetics, and Efficacy of 1.5% Ruxolitinib Gel (HDM3010) in Adult Patients with Prurigo Nodularis: A Phase I/II, Randomized, Double-Blind, Vehicle-Controlled Multicenter Clinical Trial

Dermatology And Therapy

by Chao Wu, Xuping Niu, Xiaohua Wang, Juan Su, Hengguang Zhao, Mao Lin, Chunjun Yang, Xiaoming Qin, Shuping Guo, Cunhuo Jiang, Hui Tang, Haijing Yang, Liming Wu, Min Zhu, Aihua Wei, Xiaohua Tao, Yiwen Zhang, Chang Shu, Jiawei Liu, Lu Yang, Yuetong Qian, Bingjie Zhang, Shiyu Zhang, Junfang Xu, Yang Lu, Mingjia Peng, Shizheng Luo, Weijie Ma, Hongzhong Jin
May 18, 2026

Conexiant

AAD Issues Pediatric Atopic Dermatitis Guidelines

Two companion guidelines provide 41 evidence-based recommendations on treatment and prevention, along with 29 statements on comorbidity associations in patients under 18

by Kerri Miller
April 8, 2026
6 min

Dermatology And Therapy (Springer)

Overview of Findings: Real-World Outcomes of Systemic Therapies for Moderate-to-Severe Atopic Dermatitis in Children Aged 12 and Younger from the PEDISTAD Registry

Dermatology And Therapy (Springer)

Safety, Pharmacokinetics, and Efficacy of 1.5% Ruxolitinib Gel (HDM3010) in Adult Patients with Prurigo Nodularis: A Phase I/II, Randomized, Double-Blind, Vehicle-Controlled Multicenter Clinical Trial

Original Source(s)

Safety, Pharmacokinetics, and Efficacy of 1.5% Ruxolitinib Gel (HDM3010) in Adult Patients with Prurigo Nodularis: A Phase I/II, Randomized, Double-Blind, Vehicle-Controlled Multicenter Clinical Trial

Related Content

AAD Issues Pediatric Atopic Dermatitis Guidelines

Overview of Findings: Real-World Outcomes of Systemic Therapies for Moderate-to-Severe Atopic Dermatitis in Children Aged 12 and Younger from the PEDISTAD Registry

Evaluation of Baricitinib Administration for Atopic Dermatitis Patients in Spain: Insights from the DAMA-S Retrospective Chart Analysis